护城河对比
最多三家已覆盖的公司，逐项对照。每一项判断都是人工编辑的判断，而非公司披露的数字——并且每一项都附有其引用依据。
| Micron | Wistron | Moderna | |
|---|---|---|---|
| 护城河评级 | 窄 Micron sits in a three-firm DRAM oligopoly (with Samsung and SK hynix), holds "over 60,000 patents" and leading-edge process technology (industry-first 1-gamma EUV DRAM node in FY2025), yet its FY2025 10-K concedes competitors "may use aggressive pricing" and "may have a larger market share," and consolidated gross margin swung from negative 9% (FY2023) to 40% (FY2025) — a real but commodity-cyclical, non-durable advantage. | 无 2025 年年报（向 TWSE 提交的英文译本，2026-04-28）显示的是没有受保护回报的规模：营收 NT$2.1865 trillion，增长 108%，毛利率 6.1%，合并营业利润率 3.6%，毛利增长 59.33%，而净营收增长 108.39%。年报自列的不利因素以 "Intense Price Competition and Declining Gross Profit Margins" 开篇，并称 IT 行业 "with its relatively low barriers to entry, has attracted numerous manufacturers, leading to fierce competition"；其主要买家表显示 Buyer A、Buyer E 和 Buyer I 分别占 2025 年净销售额的 39.32%、21.21% 和 12.81%。这是一家规模庞大、具备竞争力的在位企业，而其自身申报文件承认进入壁垒相对较低：无法认定存在护城河。 | 窄 The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| 护城河类型 | 无形资产与知识产权 The 10-K roots Micron's edge in proprietary technology and IP: "over 60,000 patents" granted as of Aug 28, 2025, "significant investments to develop proprietary product and process technology," the industry's first 1-gamma (EUV) DRAM node, ninth-generation G9 NAND, and HBM4 samples to key AI customers. | 无 年报的 "Competitive Niches" 章节列出的是经营能力而非持久壁垒："over 5,600 people" 的研发团队，位于台湾、美国、中国、墨西哥、捷克、越南和马来西亚的制造基地，精益制造、产品质量、供应商关系、全球物流以及经验丰富的管理团队。这些都不构成专利地位或客户锁定效应：2025 年研发费用占营收的 1.43%，公司报告 2025 年获得 120 项美国专利和 122 项台湾专利授权，而该章节对品牌客户 "each comprising an equal share of our sales" 的描述，旁边就是一张单一买家占 2025 年净销售额 39.32% 的主要买家表。 | 无形资产与知识产权 The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| 领先地位 | 并列领先者 A member of the three-supplier DRAM oligopoly and at the technology frontier (industry-first 1-gamma EUV node), but the smallest of the three by share — the 10-K acknowledges competitors "may have a larger market share" — and a later entrant scaling up in HBM behind SK hynix and Samsung. | 势均力敌 Citing MIC (February 2026), the report puts the Company at approximately 18% of the roughly 135,350K notebooks, 24% of the 39,711K desktops and 22% of the 12,370K servers manufactured in Taiwan in 2025, and lists it among the major Taiwan ODMs in every category it charts (notebooks with Quanta, Compal, Inventec and Pegatron; servers with Hon Hai, Quanta, Inventec and MiTAC). It describes this only as "considerable market competitiveness" and claims no first-place rank. | 并列领先者 The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| 定价权 | 弱 Memory is a commodity with cyclical ASPs: the 10-K flags "volatility in average selling prices" and competitors' "aggressive pricing" as key risks, and consolidated gross margin swung from -9% (FY2023) to 22% (FY2024) to 40% (FY2025), marking Micron largely as a cyclical price-taker; contract-based, supply-tight HBM is a partial exception. | 弱 2025 gross profit margin was 6.1% and consolidated operating profit margin 3.6%; gross profit rose 59.33% while net revenues rose 108.39%, so the margin narrowed. The report's first unfavorable factor is "Intense Price Competition and Declining Gross Profit Margins", and three buyers accounted for 39.32%, 21.21% and 12.81% of 2025 net sales. | 弱 Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| 综述 | Micron is one of only three scaled DRAM suppliers (with Samsung and SK hynix) and a leading-edge NAND maker, defended by proprietary product and process technology and more than 60,000 granted patents. In FY2025 it shipped the industry's first 1-gamma (EUV) DRAM production node and sampled HBM4 36GB 12-high to multiple key customers for next-generation AI platforms, evidencing process-technology leadership in AI memory (FY2025 10-K). | Wistron 是一家台湾 ODM，根据其 2025 年年报，其业务 "primarily covers the R&D, manufacturing, testing and after-sales services"，对象包括服务器与 AI 计算设备、笔记本电脑、台式机、显示器及其他电子产品，3C 电子产品占 2025 年销售额的 98.5%。营收增长逾一倍至 NT$2.1865 trillion，董事长致辞将其称为 "triple-digit percentage growth in revenue from AI and general-purpose servers"；年报还引用 MIC 数据，显示 2025 年公司约占台湾制造笔记本电脑的 18%、台式机的 24% 和服务器的 22%。与此相对，毛利率为 6.1%，年报自列的不利因素包括激烈的价格竞争、毛利率下滑以及相对较低的进入壁垒，且三家买家分别占 2025 年净销售额的 39.32%、21.21% 和 12.81%。长期计划是提高 AI 计算设备和服务器等高毛利产品的占比，制造政策则将自动化与 AI 驱动的智能制造瞄准 "higher-complexity, technically demanding product segments — expanding gross margins"——这是一条明示的通往优势的路径，而非优势已经存在的证据。 | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| 产业链位置 | US-based supplier of the memory tier of the AI stack — DRAM, HBM and NAND; the 10-K notes cloud servers for AI and data-centric workloads "require significantly increasing quantities of DRAM, including HBM," and Micron sampled HBM4 to power next-generation AI platforms. | Contract designer-manufacturer for brand and cloud customers: the report describes "professional OEM services supporting clients with world renowned brands", lists CPUs, SSDs and DRAM as main materials, and among its 2025 R&D results lists GPU servers supporting NVIDIA B300, AMD MI355 and Intel Gaudi 3. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| 产品（份额 / 壁垒） |
|
|
|
| 长周期投票 | +0.05 权重 0.20 · 群体判断 bullish 编辑先验，未经回测。 | -0.06 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | +0.05 权重 0.20 · 群体判断 bearish 编辑先验，未经回测。 |